NervGen Pharma Corp. Common stock (NGEN) Stock Ticker
Market factors today
Unlock the full NGEN picture
About NervGen Pharma Corp. Common stock
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
NGEN stock facts
| Ticker symbol | NGEN |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $154.5M |
| CEO | Adam H. Rogers |
| Employees | 8 |
| Headquarters | West Vancouver, BC, CA |
| IPO date | 2021-02-08 |
| Website | www.nervgen.com |
What you can see for NGEN on Tickr
Live NGEN price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the NGEN report.
Rankings
FAQ
What is the ticker symbol for NervGen Pharma Corp. Common stock?
The ticker symbol for NervGen Pharma Corp. Common stock is NGEN, listed on the NASDAQ Capital Market.
What is NGEN?
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and…